Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch Immunol Ther Exp (Warsz) ; 66(3): 171-181, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28861617

RESUMO

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. The number of people affected by AD is relatively high and seems to be rising. Although mild and moderate forms of the disease can be well controlled by the use of emollients, topical corticosteroids, and topical calcineurin inhibitors, treatment of severe is still a huge challenge. The new hope is biologic drugs, magic bullets in allergy, targeted at different points of the complex pathomechanism of inflammation in AD. In this review, novel biologic therapies are discussed, including recombinant monoclonal antibodies directed against various interleukin pathways (such as IL-4, IL-13, TSLP, IL-31, and IL-12/23), on immunoglobulin E, molecules acting as T cells, B cells, etc. Of biological drugs, the most promising seems to be anti-IL-4/IL-13 therapy (dupilumab-the biological agent) and phosphodiesterase-4 inhibitor (crisaborole-a small molecule). A deep understanding of the AD pathomechanism provides a new perspective for tailor-made treatment of severe atopic dermatitis.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Terapia Biológica , Inibidores de Calcineurina/uso terapêutico , Dermatite Atópica/terapia , Emolientes/uso terapêutico , Pele/imunologia , Administração Tópica , Corticosteroides/uso terapêutico , Anticorpos Monoclonais Humanizados , Compostos de Boro/uso terapêutico , Compostos Bicíclicos Heterocíclicos com Pontes/uso terapêutico , Citocinas/imunologia , Humanos , Masculino , Terapia de Alvo Molecular , Transdução de Sinais , Pele/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...